North American Malignant Hyperthermia Population
Open Access
- 1 September 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 95 (3) , 594-599
- https://doi.org/10.1097/00000542-200109000-00009
Abstract
Background: Malignant hyperthermia (MH) is a disorder of skeletal muscle manifested as a life-threatening hypermetabolic crisis in susceptible individuals after exposure to inhalational anesthetics and depolarizing muscle relaxants. Mutations in the gene encoding the skeletal muscle ryanodine receptor (RYR1) are considered a common cause of the disorder, and, to date, more than 20 RYR1 mutations have been reported in European and Canadian families. Some studies suggest that differences may exist in the frequencies and distribution of mutations in the RYR1 gene between European and North American MH families the frequency and distribution of mutations in the RYR1 gene. Methods: Skeletal muscle samples from 73 unrelated individuals diagnosed as MH susceptible according to the North American MH caffeine-halothane contracture test were studied. Genomic DNA of MH-susceptible patients was investigated by polymerase chain reaction-based restriction fragment length polymorphism, single-strand conformation polymorphism, and sequencing analysis. The majority of known RYR1 mutations were analyzed using the restriction fragment length polymorphism method, whereas new mutations were searched by single-strand conformation polymorphism in exons 12, 15, 39, 40, 44, 45, and 46 of the gene. Results: Seven known RYR1 mutations (Arg163Cys, Gly248Arg, Arg614Cys, Val2168Met, Thr2206Met, Gly2434Arg, and Arg2454His) were detected at frequencies of 2.7, 1.4, 1.4, 1.4, 1.4, 5.5, and 4.1%, respectively. In addition, three novel amino acid substitutions (Val2214Ile, Ala2367Thr, and Asp2431Asn) were detected at frequency of 1.4% each. These 10 mutations account for 21.9% of the North American MH-susceptible population. Conclusion: Three novel candidate mutations in the RYR1 gene were identified in these MH patients. The frequency and distribution of RYR1 mutations observed in this North American MH population was markedly different from that previously identified in Europe. Larger-scale studies are necessary to clarify the type and frequency of mutations in RYR1 associated with MH in North American families.Keywords
This publication has 22 references indexed in Scilit:
- Ryanodine receptor mutations in malignant hyperthermia and central core diseaseHuman Mutation, 2000
- Identification of Novel Mutations in the Ryanodine-Receptor Gene (RYR1) in Malignant Hyperthermia: Genotype-Phenotype CorrelationAmerican Journal of Human Genetics, 1998
- A Genome Wide Search for Susceptibility Loci in Three European Malignant Hyperthermia PedigreesHuman Molecular Genetics, 1997
- The Structural Organization of the Human Skeletal Muscle Ryanodine Receptor (RYR1) GeneGenomics, 1996
- Localization of the gene encoding the α2/δ-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible familiesHuman Molecular Genetics, 1994
- A mutation in the human ryanodine receptor gene associated with central core diseaseNature Genetics, 1993
- Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermiaNature, 1990
- Standardization of the Caffeine Halothane Muscle Contracture TestAnesthesia & Analgesia, 1989
- A PROTOCOL FOR THE INVESTIGATION OF MALIGNANT HYPERPYREXIA (MH) SUSCEPTIBILITYBritish Journal of Anaesthesia, 1984
- The Malignant Hyperthermia SyndromeNew England Journal of Medicine, 1983